Omalizumab and the World Health Organization. It is also used to treat people 12 years and above with chronic spontaneous urticaria (also called chronic idiopathic urticaria), which cannot be treated with elevated doses of H1-antihistamines. The main adverse effect is anaphylaxis (a life-threatening systemic allergic reaction), with a rate of occurrence of 1 to 2 patients per 1,000. Like other protein and antibody drugs, omalizumab also causes anaphylaxis, although at a relatively low frequency among antibody drugs. The allergic reaction is probably not due to the binding characteristics of the antibody drug, but to the protein nature of the antibody. The
Allergic reactions to anaesthesia Allergic reactions to anaesthesia The incidence of life-threatening hypersensitivity reactions occurring during surgery and anaesthesia is around one in 10,000 procedures. Serious allergic reactions to anesthetic medications are rare and a usually attributable to factors other than the anesthetic. Neuromuscular blocking agents, natural rubber latex, and antibiotics are the most common causes of serious allergic reactions during surgery. The mortality rate from these reactions ranges between 3-9%. Successful immediate treatment requires prompt recognition by the attending anaesthetist, or in the US, the attending anesthesiologist or nurse anesthetist. Anaesthetists are trained to recognise if an allergic reaction is occurring. The identification